title: Enhanced GABAergic tone in the ventral pallidum: memory of unpleasant experiences?
abstract: The nucleus accumbens (NAc) has emerged as an important part of the neural circuitry regulating depressive-like behaviors. Given that the NAc GABAergic medium spiny neurons project to the ventral pallidum (VP), it is reasonable to suggest that the VP may also be involved in these behaviors. Consequently, we explored the role of the VP GABAergic terminals during depressive-like behaviors in rats using the forced swim test (FST) and the sucrose preference test (SPT). Microdialysis coupled with micellar electrokinetic chromatography was used to monitor in vivo changes of GABA in the VP during the FST. GABA levels significantly increased during day-1 and day-2 during swimming, returning to the pre-swimming levels after the test. Basal concentrations of GABA on day-2 of the FST significantly increased with respect to day-1. In another set of experiments, intra-VP injections of vigabatrin (a GABA transaminase inhibitor) increased extracellular GABA and immobility behaviors in the FST while the direct GABAA receptor antagonist bicuculline reduced immobility behaviors. In the SPT, intra-VP vigabatrin injection significantly reduced preference for sucrose while bicuculline did not produce any change. At the postsynaptic side, we used semiquantitative RT-PCR to measure mRNA expression of 17 GABAA receptor subunits (α1-α6, β1-β3, γ2, δ, ε, θ, π, and ρ1-ρ3) in rats subjected to the FST. We found a significant reduction of α3 and γ2 subunit expression and an increase of δ subunit expression after day-2 in rats subject to the FST which might enhance tonic inhibition of the VP. Furthermore, immunoblot experiments revealed that protein expression of γ2 and δ subunits changed 6 days after FST in a way similar to mRNA expression. These results suggest that the enhanced VP-GABAergic tone might trigger a low motivational state, anhedonia and a possible memory mechanism for unpleasant experiences.
authors.affiliation: Laboratorio de Fisiología Celular, Decanato de Ciencias de la Salud, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venezuela, 3001-A. miguelsk@ucla.edu.ve
authors.forename: M
authors.initials: M
authors.lastname: Skirzewski
authors.forename: W
authors.initials: W
authors.lastname: López
authors.forename: E
authors.initials: E
authors.lastname: Mosquera
authors.forename: L
authors.initials: L
authors.lastname: Betancourt
authors.forename: B
authors.initials: B
authors.lastname: Catlow
authors.forename: M
authors.initials: M
authors.lastname: Chiurillo
authors.forename: N
authors.initials: N
authors.lastname: Loureiro
authors.forename: L
authors.initials: L
authors.lastname: Hernández
authors.forename: P
authors.initials: P
authors.lastname: Rada
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001640:Bicuculline / Q000008:administration & dosage / Q000494:pharmacology; D003863:Depression / Q000378:metabolism / Q000503:physiopathology*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D059330:GABAergic Neurons / Q000187:drug effects / Q000502:physiology*; D005917:Globus Pallidus / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects / Q000502:physiology*; D017551:Microdialysis / Q000379:methods; D008845:Microinjections / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000096:biosynthesis; D020888:Vigabatrin / Q000008:administration & dosage / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D058787:GABA-A Receptor Antagonists; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin; D001640:Bicuculline